Patrys

Patrys Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Patrys (PAB.AX) as of Oct 11, 2026 is 63.55 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 58.88 % — a change of 7.94% (higher).

Cash Conversion

63.55 %

YoY

7.94%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Patrys is 2026 63.55 % . Cash Conversion Rate (OCF/Net Income) of Patrys was 2025 58.88 % . It decreases by 7.94% higher compared to the previous year.

The Patrys Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
31.41 AUD
Jan 1, 2020
90.79 AUD
Jan 1, 2021
95.43 AUD
Jan 1, 2022
128.01 AUD
Jan 1, 2023
81.83 AUD
Jan 1, 2024
51.31 AUD
Jan 1, 2025
58.88 AUD
Jan 1, 2026
63.55 AUD
The Patrys Cash Conversion history
YEARCash ConversionYoY
63.55 %+7.94%
58.88 %+14.75%
51.31 %-37.30%
81.83 %-36.07%
128.01 %+34.14%
95.43 %+5.10%
90.79 %+189.09%
31.41 %-62.41%
83.56 %-30.78%
120.71 %-14.81%
141.69 %+191.67%
48.58 %-30.42%
69.82 %—
Access this data via the Eulerpool API

Patrys Stock analysis

What does Patrys do? The company Patrys Ltd is a biotechnology company based in Perth, Australia. It was founded in 2001 by a team of scientists and investors with the aim of developing and marketing targeted cancer treatments. Patrys focuses on the development of monoclonal antibodies and peptides containing therapeutic agents for cancer treatment. The main business model of Patrys is to develop and market new treatment options for cancer patients. The company utilizes the latest advancements in cancer research to develop innovative therapies tailored to the specific characteristics of each type of cancer. Patrys collaborates with leading scientists, research organizations, and pharmaceutical companies to develop a comprehensive portfolio of cancer treatments. Patrys has different business areas, all focused on the development of cancer treatments. One of these areas is the field of monoclonal antibodies, where Patrys concentrates on developing antibodies that can recognize and target specific proteins in cancer tissue. Another area focuses on the development of peptides specifically tailored to cancer cells. Patrys' products cover a variety of cancer types, including lung cancer, breast cancer, prostate cancer, colorectal cancer, and leukemia. The company's leading product is currently the antibody therapeutic PAT-LM1, used for the treatment of lung cancer. PAT-LM1 is a monoclonal antibody that targets a specific protein in the tumor, effectively combating the disease. The drug is currently in phase II clinical trials and showing promising results. Patrys is a company operating in a growing market. The global demand for cancer treatments is increasing, and Patrys has established itself as a significant player in this field. The company has gained recognition in recent years for its innovative therapy approaches and strong research and development team. Patrys aims to provide cancer patients with real hope for a cure and improve their quality of life. Overall, Patrys is a company operating in a rapidly growing market with a promising future. The company has developed a wide range of cancer treatments and works closely with leading experts and pharmaceutical companies to strengthen its position as an innovative and relevant player in cancer research. Patrys has a clear vision that it pursues, presenting an opportunity to play a significant role in the near future in a rapidly growing and highly relevant market. Patrys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Patrys stock

Cash Conversion Rate (OCF/Net Income) of Patrys is 63.55 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Patrys changed from 58.88 % to 63.55 %, representing a 7.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Patrys since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Patrys with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — Patrys

All Key Metrics — Patrys